{"id":49932,"date":"2022-10-21T19:03:32","date_gmt":"2022-10-21T17:03:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-pain-management-drugs-market-demand-and-pipeline-insights-2022-researchandmarkets-com\/"},"modified":"2022-10-21T19:03:32","modified_gmt":"2022-10-21T17:03:32","slug":"global-pain-management-drugs-market-demand-and-pipeline-insights-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-pain-management-drugs-market-demand-and-pipeline-insights-2022-researchandmarkets-com\/","title":{"rendered":"Global Pain Management Drugs Market Demand and Pipeline Insights 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) – Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)”<\/a> drug pipelines has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nAccording to the research report published in September 2022, the global Pain Management Drugs market was valued at USD 82.12 million in the year 2021 with Americas leading the regional market share.\n<\/p>\n

\nThe global pain management drugs market is driven by an increasing number of Chronic Pain diseases and the prevalence of cancer pain worldwide. Additionally, a growing population in which the number of geriatric population is high in several developing countries is anticipated to propel the growth of the global Pain Management drugs market.\n<\/p>\n

\nAdditionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This is likely to drive demand for many Pain Management drugs for advanced stages of cancer, chronic pain conditions and post-operative pain management drugs.\n<\/p>\n

\nThe COVID-19 pandemic had a mixed impact on the Global Pain Management Drugs market by affecting the drug supply chain dramatically which led to hindrances in the production and sale of opiates which are the most prominent Pain management drug in the market in key producing countries such as Afghanistan and Myanmar.\n<\/p>\n

\nParacetamol was recommended for use by various healthcare authorities across the world, to manage fever and mild pain in adults and children with COVID-19, which boosted the demand for the drug. Moreover, India and China being the chief API suppliers for Paracetamol drugs were unable to supply the APIs due to restrictions imposed due to COVID-19 which led to manufacturing restraints and shortages in many European countries.\n<\/p>\n

\nScope of the Report:<\/strong>\n<\/p>\n